NXGL NEXGEL INC

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024

LANGHORNE, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 and 11, 2024.

iAccess Alpha Virtual Conference Details:

Date: December 10-11, 2024

Presentation Day and Time: Tuesday, December 10th at 10:30 a.m. ET

Webcast:

To schedule a one-on-one investor meeting with Mr. Levy, please contact your representatives at iAccess or email KCSA Strategic Communications at .

About NEXGEL, Inc.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254



EN
21/11/2024

Underlying

NXGLNEXGEL INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXGEL INC

 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Consideration Terms of Agreement to License and Acqui...

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDA...

10h / 12m 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Signs Definitive Agreement to License and Acquire Transformativ...

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding ...

March 10, 2026 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisitio...

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acqu...

February 10, 2026 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis ...

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric ...

December 16, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applica...

December 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch